Arvinas, Inc.

NasdaqGS:ARVN Stock Report

Market Cap: US$1.5b

Arvinas Future Growth

Future criteria checks 2/6

Arvinas is forecast to grow earnings and revenue by 12% and 24.1% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be -91.3% in 3 years.

Key information

12.0%

Earnings growth rate

17.0%

EPS growth rate

Pharmaceuticals earnings growth23.8%
Revenue growth rate24.1%
Future return on equity-91.3%
Analyst coverage

Good

Last updated01 Nov 2024

Recent future growth updates

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Recent updates

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05
There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24
Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Earnings and Revenue Growth Forecasts

NasdaqGS:ARVN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026275-352-293-33015
12/31/2025222-332-266-34518
12/31/2024266-229-148-28618
9/30/2024161-309-260-258N/A
6/30/202493-323-217-215N/A
3/31/202471-355-356-354N/A
12/31/202379-367-351-348N/A
9/30/2023159-295-340-336N/A
6/30/2023158-298-323-318N/A
3/31/2023137-301-313-308N/A
12/31/2022131-282-280-273N/A
9/30/2022127-253-246-238N/A
6/30/2022103-233503510N/A
3/31/202275-213536541N/A
12/31/202154-191555559N/A
9/30/202123-180562566N/A
6/30/202121-164-142-138N/A
3/31/202121-139-118-112N/A
12/31/202026-119-96-90N/A
9/30/202024-99-83-77N/A
6/30/202047-86-59-53N/A
3/31/202045-78-52-45N/A
12/31/201943-70-47-41N/A
9/30/201942-65-42-37N/A
6/30/201915-173-54-50N/A
3/31/201914-179-51-48N/A
12/31/201814-240-19-16N/A
9/30/201813-2332224N/A
6/30/201812-114N/A28N/A
3/31/201810-98N/A31N/A
12/31/20178-29N/A5N/A
12/31/20167-12N/A-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARVN's revenue (24.1% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ARVN's revenue (24.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARVN is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y